Global Insulin Glargine Market Growth 2023-2029

Global Insulin Glargine Market Growth 2023-2029

nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).

LPI (LP Information)' newest research report, the “Insulin Glargine Industry Forecast” looks at past sales and reviews total world Insulin Glargine sales in 2022, providing a comprehensive analysis by region and market sector of projected Insulin Glargine sales for 2023 through 2029. With Insulin Glargine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Insulin Glargine industry.

This Insight Report provides a comprehensive analysis of the global Insulin Glargine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Insulin Glargine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Insulin Glargine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Insulin Glargine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Insulin Glargine.

The global Insulin Glargine market size is projected to grow from US$ 6562.1 million in 2022 to US$ 8722.5 million in 2029; it is expected to grow at a CAGR of 8722.5 from 2023 to 2029.

Global Insulin Glargine key players include Sanofi-Aventis, Ganlee, etc. Global top two manufacturers hold a share nearly 50%.

USA is the largest market, with a share over 60%, followed by China, and Europe, both have a share about 35 percent.

In terms of product, Pre-filled Syringe is the largest segment, with a share about 75%. And in terms of application, the largest application is Treat type2 diabetes, followed by Treat type1 diabetes.

This report presents a comprehensive overview, market shares, and growth opportunities of Insulin Glargine market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Single Dose Vial

Pre-filled Syringe

Segmentation by application

Treat Type2 Diabetes

Treat Type1 Diabetes

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Sanofi-Aventis

Ganlee

Biocon

Key Questions Addressed in this Report

What is the 10-year outlook for the global Insulin Glargine market?

What factors are driving Insulin Glargine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Insulin Glargine market opportunities vary by end market size?

How does Insulin Glargine break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.